Trials / Conditions / NRG1 Fusion
NRG1 Fusion
4 registered clinical trials studyying NRG1 Fusion — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Enrolling By Invitation | Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance NCT07122882 | Chang Gung Memorial Hospital | — |
| Terminated | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumo NCT03805841 | Rain Oncology Inc | Phase 2 |
| Active Not Recruiting | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) NCT02912949 | Partner Therapeutics, Inc. | Phase 2 |
| Approved For Marketing | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusio NCT04100694 | Merus B.V. | — |